Back to Search Start Over

SARS-CoV-2 in severe COVID-19 induces a TGF-β-dominated chronic immune response that does not target itself.

Authors :
Ferreira-Gomes M
Kruglov A
Durek P
Heinrich F
Tizian C
Heinz GA
Pascual-Reguant A
Du W
Mothes R
Fan C
Frischbutter S
Habenicht K
Budzinski L
Ninnemann J
Jani PK
Guerra GM
Lehmann K
Matz M
Ostendorf L
Heiberger L
Chang HD
Bauherr S
Maurer M
Schönrich G
Raftery M
Kallinich T
Mall MA
Angermair S
Treskatsch S
Dörner T
Corman VM
Diefenbach A
Volk HD
Elezkurtaj S
Winkler TH
Dong J
Hauser AE
Radbruch H
Witkowski M
Melchers F
Radbruch A
Mashreghi MF
Source :
Nature communications [Nat Commun] 2021 Mar 30; Vol. 12 (1), pp. 1961. Date of Electronic Publication: 2021 Mar 30.
Publication Year :
2021

Abstract

The pathogenesis of severe COVID-19 reflects an inefficient immune reaction to SARS-CoV-2. Here we analyze, at the single cell level, plasmablasts egressed into the blood to study the dynamics of adaptive immune response in COVID-19 patients requiring intensive care. Before seroconversion in response to SARS-CoV-2 spike protein, peripheral plasmablasts display a type 1 interferon-induced gene expression signature; however, following seroconversion, plasmablasts lose this signature, express instead gene signatures induced by IL-21 and TGF-β, and produce mostly IgG1 and IgA1. In the sustained immune reaction from COVID-19 patients, plasmablasts shift to the expression of IgA2, thereby reflecting an instruction by TGF-β. Despite their continued presence in the blood, plasmablasts are not found in the lungs of deceased COVID-19 patients, nor does patient IgA2 binds to the dominant antigens of SARS-CoV-2. Our results thus suggest that, in severe COVID-19, SARS-CoV-2 triggers a chronic immune reaction that is instructed by TGF-β, and is distracted from itself.

Details

Language :
English
ISSN :
2041-1723
Volume :
12
Issue :
1
Database :
MEDLINE
Journal :
Nature communications
Publication Type :
Academic Journal
Accession number :
33785765
Full Text :
https://doi.org/10.1038/s41467-021-22210-3